Rainer Fuchs Email & Phone Number

Budapest, Hungary

Portland, Maine

Formerly Egenix Pharmaceuticals

Boston

Boston

http://www.egenixinc.com/index.htmOncology startup

Cambridge, MA

Biotech startup, focused on preclinical research related to SDF-1 and its use as therapeutic in cardiovascular diseases and diabetic wound healing. Founded by Rich Lee and Vincent Segers at MGH, funded by Biogen Idec Innovation Incubator and Partners Innovation Fund. Provasculon was acquired by Mesoblast in 2013.

Responsible for all information technology solutions for drug discovery, development, clinical, regulatory, drug safety, and quality at Biogen Idec.

Conceived of and implemented a novel model for creating early-stage (preclinical) drug discovery companies. BI3 (Biogen Idec Innovation Incubator) provides funding, facilities, scientific and technology support, and operational management to new companies aiming to bring drug candidates into the clinic in a 3 to 4 year time frame (www.biogenidec.com/bi3)..

Overseeing Oncology, Molecular Technologies, Informatics and Operations

Responsibilities include:- Research Informatics (computational drug design, computational biology, laboratory workflow management, decision support systems);- Research Operations (financial and resource management, scientific project and portfolio management);- Corporate Library and Information Services;- Division-wide infrastructure services.

Responsible for leadership in drug discovery informatics worldwide.

Responsible for Scientific Computing (biological, chemical and assay data management and analysis) and Information Technology (MIS) departments.

The Hoechst-ARIAD Genomics Center (HAGC) was a 50/50 joint venture of ARIAD and Hoechst Marion Roussel (HMR) engaged in genomics research, primarily in the fields of osteoporosis and oncology. With the sale of ARIAD’s interest in HAGC to Aventis in 1999, the HAGC became the Aventis Cambridge Genomics Center and the worldwide center of excellence in.

Created and directed Glaxo’s US Bioinformatics program. The department’s main responsibility was to enable and promote the use of genomics information for target identification and selection by all drug discovery projects, and to address all computational components of Glaxo’s genetics research program, including statistical genetics, physical mapping.

Staff Scientist in EMBL Data Library, focused on enhancing contents of and access to EMBL sequence databases. Research in sequence analysis.

Ph.D.

Diplom (M.S.)